Prophylactic growth factor (GF) support with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-negative breast cancer (BC): An interim safety analysis of the GEICAM 9805 study

Martín, M. González; Lluch, Aña; Seguí, Miguel Àngel; Anton, A.; Ruíz, A Navarro; Ramos, M.; Rodriguez-Lescure, A.; Adrover, Encarna

doi:10.1200/jco.2004.22.14_suppl.620

Cited by 20 publications

(15 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This would result in a further increase in up-front drug costs but a reduced rate of hospitalizations due to febrile neutropenia for the TAC strategy. In this alternate model the rate of febrile neutropenia for adjuvant TAC patients was decreased from 24.7% to 3.5% [28].…”

Section: Discussionmentioning

confidence: 99%

Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effects

Golmohammadi

Younis

et al. 2008

Breast Cancer Res Treat

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effects

Golmohammadi

Younis

et al. 2008

Breast Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…According to previous studies (16)(17)(18)(19)(20)(21)(22), the FN proportion for each regimen is estimated as approximately 10% for EC (AC) (16); 20% for TC (17,18), FEC (19), DOC (20) and TCbH (21); and 30% for TAC (22) at the adjuvant setting in Japanese patients. When the true proportion is 10 or 20%, the necessary number of cases is 165 or 264 to achieve an admissible 95% CI.…”

Section: Discussionmentioning

confidence: 99%

Prospective cohort study of febrile neutropenia in breast cancer patients with neoadjuvant and adjuvant chemotherapy: CSPOR-BC FN study

Ishikawa

Sakamaki

Narui

et al. 2016

Jpn. J. Clin. Oncol.

View full text Add to dashboard Cite

With the increasing use of adjuvant chemotherapy for treating early breast cancer, febrile neutropenia management has become crucial. Guidelines for febrile neutropenia management are mostly based on a Caucasian population survey although ethnic differences are reported in terms of adverse events. We survey the current status of febrile neutropenia and risk factors in Japanese female breast cancer patients receiving neoadjuvant and adjuvant chemotherapy regimens potential for febrile neutropenia. Subsequently, we plan to conduct a multicenter prospective cohort study involving 1000 patients with operable breast cancer. With the current state of oral antibiotics being routinely prescribed without hematology tests, we survey febrile neutropenia based on two different definitions, namely, true febrile neutropenia: ≥37.5°C and Grade 4 neutropenia, and surrogate febrile neutropenia: ≥37.5°C and oral antibiotic and antipyretic intake. The comparison of true febrile neutropenia and surrogate febrile neutropenia incidences is anticipated to provide information on the safety and feasibility of chemotherapy management without performing blood tests.

show abstract

“…2 Primary prophylaxis with G-CSF for docetaxel-doxorubicin combinations does not fully match the current American Society of Clinical Oncology guidelines, which establish a threshold of 40% neutropenic fever rate, and the prescribing information for docetaxel does not specify the use of G-CSF. However, we believe that the reported incidence of 25% would in fact justify such routine use.…”

Section: Life-threatening Complications From Doxorubicin-docetaxel Chmentioning

confidence: 99%

“…Following the addition of prophylactic G-CSF in the GEICAM trial, the rate of febrile neutropenia associated with the docetaxel-doxorubicincyclophosphamide regimen fell below 10%. 2 The controversial use of prophylactic antibiotics, favoring the emergence of resistant bacteria without lowering the risk of death, 3 did not achieve this level of protection, as found in the NSABP, GEICAM, BCIRG, and Eastern Cooperative Oncology Group (ECOG) trials. It may, however, explain the lower rate of febrile neutropenia in these studies as compared with ours, which did not include prophylactic antibiotic use (around 25% vs 41%).…”

Section: Life-threatening Complications From Doxorubicin-docetaxel Chmentioning

confidence: 99%

Gender-Based Violence in Women and Mental Disorders

Rosmalen-Nooijens¹,

Wong²,

Lagro-Janssen³

2011

JAMA: The Journal of the American Medical Association

View full text Add to dashboard Cite

and colleagues 1 studied the prevalence of gender-based violence (GBV) among women and the relationship with mental disorders and psychosocial function. However, they did not comment on the possible role of intergenerational transmission of violence: children exposed to violence have a high chance to abuse or be abused in their adult life. 2 In the article, Table 2 shows that women who reported any childhood nonsexual trauma had the highest prevalence of GBV later in life (55.77%), which is higher than any other patient characteristic described in the table. Unfortunately, the researchers did not investigate the association between nonsexual childhood trauma, GBV, and mental disorders. Early support for children exposed to violence may be an important factor to prevent intergenerational transmission and therefore GBV and associated mental disorders, just as social support is important to reduce GBV and the negative mental health effects of GBV. 3 The authors collected data on social support but used it only as a control factor.

show abstract

Prophylactic growth factor (GF) support with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-negative breast cancer (BC): An interim safety analysis of the GEICAM 9805 study

Cited by 20 publications

References 0 publications

Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effects

Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effects

Prospective cohort study of febrile neutropenia in breast cancer patients with neoadjuvant and adjuvant chemotherapy: CSPOR-BC FN study

Gender-Based Violence in Women and Mental Disorders

Contact Info

Product

Resources

About